A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Tardive Dyskinesia

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Tardive Dyskinesia

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Valbenazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Registrational; Therapeutic Use
  • Acronyms KINECT-2
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 27 Apr 2018 Results of a pooled analysis from KINECT, KINECT 2, and KINECT 3 studies assessing minimal clinically important difference (MCID) for Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score in tardive dyskinesia, presented at the 70th Annual Meeting of the American Academy of Neurology
    • 07 Dec 2017 Results (n=400) assessing the cardiovascular effects of once-daily valbenazine using pooled data from three 6-week, double-blind, placebo-controlled trials (KINECT, KINECT 2, and KINECT 3) and the 42-week valbenazine extension period of KINECT 3, published in the Drug Safety Journal.
    • 04 Dec 2017 According to a Neurocrine Biosciences media release, Results (n=373) of pooled population from KINETIC-1,KINETIC-2,KINETIC-3 studies presented at the College of Neuropsychopharmacology (ACNP) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top